A WHO consultation identified the most vulnerable groups as elderly individuals, infants, preschool-aged children, and pregnant or lactating women, due to either increased nutritional demands or impaired absorption capacity (de Benoist, 2008)
Week 17 and Beyond: Maintenance Dose (2.4mg for Wegovy) By the time the full maintenance dose is reached, the majority of patients experience significantly reduced side effect burden compared to the early weeks
Springer Nature
Human clinical-trial data (Phase 1/2 studies in wound healing, cardiac injury, and dry eye) exist only for a different, full-length recombinant thymosin beta-4 product, not for the short synthetic fragment marketed as TB-500, so no completed published human trial has evaluated TB-500 specifically for muscle, tendon, or joint recovery